{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":20,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":20,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"fe933d0e8be0","filters":{"venue":"Therapeutic Advances in Hematology"}},"results":[{"id":"W2122059243","doi":"10.1177/2040620715571077","title":"Targeting polo-like kinase 1 in acute myeloid leukemia","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"PLK1; Medicine; Cytarabine; Myeloid leukemia; Leukemia; Polo-like kinase; Myeloid; Clinical trial; Oncology; Cancer research; Internal medicine; Cell cycle; Pharmacology; Cancer","authors":[{"name":"Joseph Brandwein","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05368819906423131,"gpt":0.4039952893888705,"spread":0.3503070903246392,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001357213,0.0009505922,0.005367553,0.001303375,0.00005919144,0.00001827818,0.0008415497,0.001164993,0.0002567104],"category_scores_gemma":[0.0002371361,0.0007650434,0.0003679898,0.00158543,0.0005435051,0.0002537374,0.0003816352,0.002840116,0.0004153326],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003760135,"about_ca_system_score_gemma":0.0033872,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005752794,"about_ca_topic_score_gemma":0.00004963743,"domain_scores_codex":[0.9940497,0.0008346635,0.001809272,0.001197112,0.0005752965,0.001533999],"domain_scores_gemma":[0.9970098,0.000895842,0.0005599509,0.001067533,0.0001505724,0.0003163629],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000272372,0.0001284788,0.0002085511,0.01212375,0.0002567806,0.003452864,0.0002041958,0.00001129503,0.000004200888,0.001427096,0.0003805546,0.9815299],"study_design_scores_gemma":[0.002105073,0.0002312587,0.000003452934,0.006890468,0.0005003712,0.002990731,0.0001610414,0.0001531593,0.000006204184,0.001654426,0.9846825,0.0006213074],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007103778,0.9943616,0.0001561829,0.0001914528,0.0006440155,0.002242541,0.0000245962,0.0001263873,0.002182175],"genre_scores_gemma":[0.0001501227,0.9955947,0.001813786,0.00044681,0.000194323,0.0006243559,0.0002600664,0.0002055047,0.0007103595],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9843019,"threshold_uncertainty_score":0.9994801,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4226103605","doi":"10.1177/20406207221085202","title":"International consensus recommendations on the management of people with haemophilia B","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Spark Therapeutics; Genentech; Grifols; Swedish Orphan Biovitrum; Baxalta; CSL Behring; Biogen; Novo Nordisk; Sanofi; Chugai Pharmaceutical; McMaster University; Pfizer","keywords":"Haemophilia; Medicine; Haemophilia B; Haemophilia A; Delphi method; Intensive care medicine; Delphi; Pediatrics","authors":[{"name":"Daniel P. Hart","is_ca":false},{"name":"Davide Matino","is_ca":true},{"name":"Jan Astermark","is_ca":false},{"name":"Gerard Dolan","is_ca":false},{"name":"Roseline d’Oiron","is_ca":false},{"name":"Cédric Hermans","is_ca":false},{"name":"Víctor Jiménez‐Yuste","is_ca":false},{"name":"Adriana Linares","is_ca":false},{"name":"Tadashi Matsushita","is_ca":false},{"name":"Simon McRae","is_ca":false},{"name":"Margareth C. Ozelo","is_ca":false},{"name":"Sean Platton","is_ca":false},{"name":"Darrel W. Stafford","is_ca":false},{"name":"Robert F. Sidonio","is_ca":false},{"name":"Andreas Tiede","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1047656392073772,"gpt":0.423291382229807,"spread":0.3185257430224298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002530444,0.0002281525,0.001003541,0.0002503388,0.00006948953,0.000003702139,0.000286044,0.00008014453,0.002044369],"category_scores_gemma":[0.00001209093,0.0001210434,0.0001420628,0.0004210628,0.0001845221,0.00001653024,0.00009666793,0.0004433565,0.00002626299],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001497845,"about_ca_system_score_gemma":0.0001012099,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002603536,"about_ca_topic_score_gemma":0.000006143634,"domain_scores_codex":[0.9985047,0.0002219711,0.0004501934,0.0002984424,0.0003003011,0.000224383],"domain_scores_gemma":[0.9982718,0.001009799,0.0002204793,0.0004369667,0.00002875951,0.00003218001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001556269,0.0003299858,0.0001231981,0.004404927,0.0008512901,0.0001792691,0.00009876836,0.000001928865,2.964021e-8,0.03148717,0.00007818104,0.9622896],"study_design_scores_gemma":[0.0005743628,0.0002476493,0.000007174479,0.003726568,0.000383671,0.0004922246,0.0003309468,0.000007325102,0.000002122498,0.0007201146,0.9934052,0.0001026726],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004120544,0.9743575,0.00001424317,0.003920516,0.000247299,0.001423222,0.00002360572,0.00001803356,0.01995438],"genre_scores_gemma":[0.0003973738,0.9973686,0.0005370482,0.00008677502,0.00002199352,0.0006366171,0.000118585,0.00003018463,0.0008027876],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.993327,"threshold_uncertainty_score":0.9988679,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3094234317","doi":"10.1177/2040620720966137","title":"One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Hematology Association; Alexion Pharmaceuticals","keywords":"Eculizumab; Paroxysmal nocturnal hemoglobinuria; Medicine; Internal medicine; Immunology; Antibody; Complement system","authors":[{"name":"Hubert Schrezenmeier","is_ca":false},{"name":"Austin Kulasekararaj","is_ca":false},{"name":"Lindsay Mitchell","is_ca":false},{"name":"Flore Sicre de Fontbrune","is_ca":false},{"name":"Timothy Devos","is_ca":false},{"name":"Shinichiro Okamoto","is_ca":false},{"name":"Richard A. Wells","is_ca":true},{"name":"Scott T. Rottinghaus","is_ca":false},{"name":"Peng Liu","is_ca":false},{"name":"Stephan Ortiz","is_ca":false},{"name":"Jong Wook Lee","is_ca":false},{"name":"Gèrard Socié","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03983949947990802,"gpt":0.324679299457079,"spread":0.284839799977171,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006184641,0.0002825956,0.001910987,0.0001639216,0.0000519639,0.000006772244,0.0004467701,0.00008835919,0.0002082847],"category_scores_gemma":[0.0001136766,0.0002220265,0.0000452242,0.0003251108,0.0003692539,0.0001114737,0.0002930858,0.0001978387,0.000007400053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003745145,"about_ca_system_score_gemma":0.00007678978,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009337511,"about_ca_topic_score_gemma":0.0002290097,"domain_scores_codex":[0.9964893,0.001219322,0.001279844,0.0005465018,0.0001059271,0.000359123],"domain_scores_gemma":[0.9980875,0.000924541,0.0004871769,0.0003452879,0.0001066395,0.00004886483],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8921115,0.004990737,0.05544725,0.0004832559,0.0007690442,0.00002667464,0.01532913,0.000147128,0.01163415,0.004390691,0.00002931694,0.01464112],"study_design_scores_gemma":[0.9446072,0.008724972,0.0197589,0.001596614,0.0001813262,0.00006393109,0.009523218,0.00007882699,0.0129491,0.0009306333,0.0009707226,0.0006145604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9729367,0.02030195,0.0003149402,0.000560792,0.0001252426,0.005639825,0.00002777962,0.00001993094,0.00007286883],"genre_scores_gemma":[0.998458,0.0004115592,0.0006042612,0.0002280153,0.00001047916,0.0002432816,0.00001822809,0.00002228263,0.000003884279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0524957,"threshold_uncertainty_score":0.9053978,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4285185611","doi":"10.1177/20406207221091046","title":"The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Paroxysmal nocturnal hemoglobinuria; Eculizumab; Medicine; Complement system; Complement component 5; Immunology; CD59; Complement (music); Internal medicine; Antibody","authors":[{"name":"Austin Kulasekararaj","is_ca":false},{"name":"Robert A. Brodsky","is_ca":false},{"name":"Jun‐ichi Nishimura","is_ca":false},{"name":"Christopher J. Patriquin","is_ca":true},{"name":"Hubert Schrezenmeier","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05434598404694474,"gpt":0.3689961274477568,"spread":0.3146501434008121,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007739375,0.0004567525,0.002018074,0.0002780036,0.0001732428,0.000007605997,0.0005780766,0.0002154667,0.002001909],"category_scores_gemma":[0.00005335832,0.0003328701,0.0003020347,0.0003949395,0.0004864162,0.00008267189,0.0003089945,0.0007010776,0.00003331915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003070518,"about_ca_system_score_gemma":0.0002507596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001619154,"about_ca_topic_score_gemma":0.0004861296,"domain_scores_codex":[0.9952176,0.001511323,0.002003543,0.0005215428,0.0001033994,0.0006425462],"domain_scores_gemma":[0.9963223,0.001761078,0.001254206,0.0006203899,0.00002372865,0.00001825228],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002929583,0.0004533464,0.004905627,0.007695996,0.0003035481,0.0002076167,0.000239385,0.0000124311,0.000009779545,0.02974152,0.0001947006,0.9559431],"study_design_scores_gemma":[0.0009193341,0.0001390684,0.00006367449,0.002076594,0.0001479583,0.001223403,0.0003348552,0.000001404105,0.00002136127,0.003379456,0.9913979,0.0002949659],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007394066,0.9963232,0.00002210447,0.00004447681,0.0009771981,0.001398269,0.0001128974,0.00002398738,0.0003585114],"genre_scores_gemma":[0.01201022,0.9865545,0.00002374378,0.00005147155,0.00002333587,0.0009523394,0.0002869645,0.0000358524,0.00006159481],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9912032,"threshold_uncertainty_score":0.9999123,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3094556560","doi":"10.1177/2040620720966888","title":"Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Haemophilia; Dosing; Clotting factor; Haemophilia A; Intensive care medicine; Trough level; Population; Pharmacokinetics; Surgery; Internal medicine","authors":[{"name":"Cédric Hermans","is_ca":false},{"name":"G. Dolan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1926136747927358,"gpt":0.5560222201151694,"spread":0.3634085453224336,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001335321,0.0004861743,0.003827789,0.0002194533,0.00003620883,0.00001170463,0.0001665243,0.0004525131,0.0002110051],"category_scores_gemma":[0.00214936,0.0003541928,0.0002624264,0.0006038653,0.0004299404,0.0002174999,0.0001455774,0.001732576,0.00009193901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001516549,"about_ca_system_score_gemma":0.0008933971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002299322,"about_ca_topic_score_gemma":0.000003246613,"domain_scores_codex":[0.9950357,0.001400284,0.001871001,0.0007766674,0.0004169606,0.0004993823],"domain_scores_gemma":[0.9942497,0.004543847,0.0004580841,0.0004061928,0.0001114493,0.0002307327],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002214347,0.0005703879,0.0002696075,0.05355877,0.0002330528,0.002481163,0.0000495132,1.438064e-7,5.48592e-8,0.005884662,0.0002429518,0.9364883],"study_design_scores_gemma":[0.001620647,0.0003010775,0.000008911852,0.02199438,0.00123607,0.00460594,0.00004045488,0.00006145454,4.669286e-7,0.0009254203,0.9689451,0.0002600769],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000003697102,0.9760145,0.00005319526,0.01891614,0.0002125801,0.003108931,0.00001471054,0.00003420526,0.001642034],"genre_scores_gemma":[0.00003425268,0.9934526,0.002814791,0.002661715,0.0002406948,0.0003885993,0.0001220203,0.00006066671,0.0002246813],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9687021,"threshold_uncertainty_score":0.999891,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4402541521","doi":"10.1177/20406207241275376","title":"Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Ipsen; GlaxoSmithKline","keywords":"Medicine; Myeloid; Internal medicine; Oncology","authors":[{"name":"Justin M. Watts","is_ca":false},{"name":"Mark D. Minden","is_ca":true},{"name":"Kimo Bachiashvili","is_ca":false},{"name":"Andrew M. Brunner","is_ca":false},{"name":"Sameem Abedin","is_ca":false},{"name":"Timothy Crossman","is_ca":false},{"name":"Magdalena Zając","is_ca":false},{"name":"V. V. Moroz","is_ca":false},{"name":"Jacqueline L. Egger","is_ca":false},{"name":"Aarti Tarkar","is_ca":false},{"name":"Brandon E. Kremer","is_ca":false},{"name":"Olena Barbash","is_ca":false},{"name":"Gautam Borthakur","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01123824306989505,"gpt":0.329394950144116,"spread":0.3181567070742209,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000176992,0.0001004866,0.0002575413,0.00004741737,0.00002044315,0.000001633541,0.00009750117,0.0001087769,0.00000358432],"category_scores_gemma":[0.0000184148,0.00006935513,0.00003007016,0.0001847948,0.0002043541,0.000008613608,0.00008106926,0.0001244976,1.307703e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001278249,"about_ca_system_score_gemma":0.00005541029,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001174267,"about_ca_topic_score_gemma":0.0005193686,"domain_scores_codex":[0.9990381,0.000164787,0.000334692,0.0002589494,0.00008848176,0.0001150024],"domain_scores_gemma":[0.9995214,0.00007198081,0.0001195981,0.0002429662,0.00002910881,0.00001492984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007014502,0.004313595,0.6214869,0.0002003217,0.00020089,0.000002797854,0.0009623952,0.001460394,0.008342244,0.0006128537,0.000004560659,0.3553986],"study_design_scores_gemma":[0.0414519,0.02930478,0.8222226,0.0005272995,0.0002603463,0.00004956659,0.0008701295,0.0021484,0.093773,0.002692522,0.005950515,0.0007489486],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994633,0.004362959,0.0002778996,0.00005147797,0.0001782017,0.0004493721,0.000006007777,0.000003753442,0.00003734259],"genre_scores_gemma":[0.99954,0.0003394669,0.00005405728,0.00001230569,0.00001340777,0.00001449499,0.000004065505,0.00001069438,0.00001150358],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3546496,"threshold_uncertainty_score":0.282822,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2160410546","doi":"10.1177/2040620712471553","title":"The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Anaplastic lymphoma kinase; Cancer research; Carcinogenesis; Anaplastic large-cell lymphoma; Tyrosine kinase; STAT protein; Signal transduction; STAT3; Biology; Medicine; Lymphoma; Cell biology; Cancer; Pathology; Immunology; Internal medicine; Lung cancer","authors":[{"name":"Raymond Lai","is_ca":true},{"name":"Robert J. Ingham","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01015474149840613,"gpt":0.2801749200807791,"spread":0.270020178582373,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000144247,0.0001733517,0.0004555353,0.00003946297,0.0000971615,0.000006007993,0.0002327322,0.0001034998,0.0001306232],"category_scores_gemma":[0.00005375997,0.00008203227,0.000123241,0.0002053611,0.0005299303,0.00006248582,0.00008733277,0.0001265792,0.00005920928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007034304,"about_ca_system_score_gemma":0.00008474189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006548502,"about_ca_topic_score_gemma":0.0001021391,"domain_scores_codex":[0.998697,0.0001706483,0.0004238446,0.000240239,0.0001125407,0.0003557269],"domain_scores_gemma":[0.9986301,0.0004775742,0.0001894246,0.0005855711,0.00007077694,0.00004653347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004746912,0.001223777,0.389693,0.0001381483,0.0002999797,0.0000828294,0.0004684963,0.00001850237,0.004094176,0.1560126,0.0003796074,0.4471142],"study_design_scores_gemma":[0.01527259,0.001826278,0.3405692,0.0005075096,0.0005751075,0.002987612,0.0009623824,0.0005255663,0.1128808,0.1246431,0.3985776,0.0006722691],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8884607,0.09808639,0.00007201197,0.01000623,0.0004923446,0.00110621,0.000006482542,0.00003142007,0.001738199],"genre_scores_gemma":[0.9916842,0.006024445,0.0001908663,0.001674092,0.00002945745,0.0002595262,0.000004743946,0.00001518741,0.0001174786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4464419,"threshold_uncertainty_score":0.3345179,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3112714545","doi":"10.1177/2040620720977039","title":"Adverse events in second- and third-line treatments for acute and chronic graft- <i>versus</i> -host disease: systematic review","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Extracorporeal Photopheresis; Graft-versus-host disease; Adverse effect; Internal medicine; Incidence (geometry); Hematopoietic stem cell transplantation; Population; Disease; Immunology","authors":[{"name":"Vladica Veličković","is_ca":false},{"name":"Emily McIlwaine","is_ca":false},{"name":"Rongrong Zhang","is_ca":false},{"name":"Tim Spelman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0370342065950142,"gpt":0.3841141538634325,"spread":0.3470799472684183,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002841576,0.0006441794,0.004985624,0.0002115984,0.00003916623,0.000003070817,0.000163458,0.0002573119,0.0000321951],"category_scores_gemma":[0.00007357197,0.0004886842,0.0002603233,0.0003381559,0.000125808,0.0001332911,0.0000418578,0.0003178767,0.00001864782],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000257623,"about_ca_system_score_gemma":0.0002935055,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":8.649868e-7,"about_ca_topic_score_gemma":0.00003730226,"domain_scores_codex":[0.9967875,0.0003451962,0.00146945,0.0007570026,0.000202058,0.0004387989],"domain_scores_gemma":[0.9976879,0.001079259,0.000552983,0.0004390736,0.00003367932,0.0002070713],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0002637841,0.00009322541,0.00006703976,0.9830615,0.0008140676,0.0002672758,0.00009148213,1.190602e-7,8.280072e-7,0.0005335327,0.000002168393,0.01480501],"study_design_scores_gemma":[0.007095067,0.000623511,0.00001346407,0.9013543,0.02698787,0.001561078,0.00005022051,0.00006667563,0.000005722123,0.0003772549,0.06126177,0.0006031311],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003396304,0.9894933,0.0002310757,0.0001811228,0.0002076647,0.009625752,0.0001308022,0.00004277669,0.00005352326],"genre_scores_gemma":[0.0001566912,0.9962333,0.0002718717,0.0003106419,0.00003279155,0.002539469,0.0002805823,0.00008144401,0.0000931894],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.08170723,"threshold_uncertainty_score":0.9997565,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2756236937","doi":"10.1177/2040620717729128","title":"Red cell genotyping precision medicine: a conference summary","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Héma-Québec","funders":"NIH Clinical Center; U.S. Department of Health and Human Services; National Institutes of Health; Grifols; Australian Government; Canadian Blood Services","keywords":"Genotyping; Precision medicine; Medicine; Clinical Practice; Medical physics; Family medicine; Pathology; Genotype; Genetics; Biology","authors":[{"name":"Gregory A. Denomme","is_ca":false},{"name":"Waseem Q. Anani","is_ca":false},{"name":"Neil D. Avent","is_ca":false},{"name":"Gregor Bein","is_ca":false},{"name":"Lynne Briggs","is_ca":false},{"name":"Razvan Lapadat","is_ca":false},{"name":"Celina Montemayor","is_ca":false},{"name":"María Rios","is_ca":false},{"name":"Maryse St‐Louis","is_ca":true},{"name":"Lynne Uhl","is_ca":false},{"name":"Silvano Wendel","is_ca":false},{"name":"Willy A. Flegel","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1255519246318827,"gpt":0.4248344417129931,"spread":0.2992825170811104,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003785516,0.0005721368,0.003822263,0.000357822,0.0001288091,0.00001158939,0.0005123615,0.0006835994,0.0002665684],"category_scores_gemma":[0.00006931606,0.0003950142,0.000284826,0.0002003515,0.0004123023,0.0001411832,0.00009582937,0.0009335855,0.00005116137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007428438,"about_ca_system_score_gemma":0.0002821156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001577717,"about_ca_topic_score_gemma":0.00003800197,"domain_scores_codex":[0.9971445,0.0002501399,0.001069193,0.000753922,0.0002729184,0.0005093938],"domain_scores_gemma":[0.9975101,0.0005693551,0.0006134422,0.001097459,0.0000819232,0.0001277486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009845969,0.0001112314,0.00002865987,0.01915431,0.00006239369,0.000251384,0.0001103585,2.452999e-7,0.00000236029,0.001635176,0.00002326269,0.9785222],"study_design_scores_gemma":[0.001361522,0.0002787113,0.000006343588,0.04043603,0.0009686119,0.001369289,0.00002719633,0.00002312227,0.000006429977,0.00326047,0.9519364,0.0003259271],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000005721312,0.9825933,0.001007541,0.0002336022,0.0007004082,0.001411879,0.000005627224,0.00006435231,0.01397756],"genre_scores_gemma":[0.0006560268,0.9975337,0.0006513232,0.0001358059,0.0001834472,0.0001492882,0.00006700009,0.00007716003,0.0005462079],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9781962,"threshold_uncertainty_score":0.9998502,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168385579","doi":"10.1177/2040620715586528","title":"Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Fludarabine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide; Leukemia; Venetoclax; Immunology; Lymphoma","authors":[{"name":"Carolyn Owen","is_ca":true},{"name":"Douglas A. Stewart","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06151108374895914,"gpt":0.4038393252012171,"spread":0.3423282414522579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002395892,0.0006522856,0.003503064,0.0002363926,0.000067041,0.00001025893,0.000278177,0.000371492,0.00003095643],"category_scores_gemma":[0.00006812648,0.0003335607,0.0002750061,0.0005128421,0.0007770278,0.0000837588,0.00005923505,0.0002204369,0.000007972583],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1830799,"about_ca_system_score_gemma":0.04559017,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003293423,"about_ca_topic_score_gemma":0.0002451775,"domain_scores_codex":[0.9971879,0.0002304171,0.0008023535,0.0007231907,0.0003734701,0.0006826922],"domain_scores_gemma":[0.9963374,0.00178498,0.0005101166,0.0008649696,0.0003688798,0.0001336125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001265346,0.0001652323,0.00003134321,0.02789124,0.001251924,0.00005465818,0.0007163818,0.0000613376,1.89462e-8,0.004628184,0.00001029077,0.9639241],"study_design_scores_gemma":[0.03788437,0.006785625,0.000005629139,0.01018444,0.004384061,0.0008189679,0.000236274,0.001341279,0.000004569803,0.00115199,0.9367802,0.0004226201],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003033878,0.9920673,0.00008973394,0.00001444338,0.0001019583,0.007191779,0.00005043616,0.00003431863,0.0001466091],"genre_scores_gemma":[0.001261226,0.9965869,0.0001192653,0.00002341544,0.00007277459,0.001574978,0.00008937774,0.0001039372,0.0001681287],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9635014,"threshold_uncertainty_score":0.9999117,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2102216347","doi":"10.1177/2040620712453067","title":"Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism","year":2012,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Hamilton Health Sciences; Hamilton General Hospital","funders":"Bayer HealthCare","keywords":"Medicine; Rivaroxaban; Dabigatran; Apixaban; Edoxaban; Deep vein; Pulmonary embolism; Atrial fibrillation; Thrombosis; Intensive care medicine; Warfarin; Surgery; Internal medicine","authors":[{"name":"Alexander G.G. Turpie","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03052497582906794,"gpt":0.3507486128392116,"spread":0.3202236370101437,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002925277,0.0001570217,0.000717829,0.0001289385,0.00003333066,0.000002933327,0.00006099795,0.00005942675,0.00001181951],"category_scores_gemma":[0.00001654909,0.0000857709,0.00004303033,0.0002077434,0.0002483805,0.0001982454,0.0000187407,0.00005341134,4.836025e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005502146,"about_ca_system_score_gemma":0.00001595144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009650044,"about_ca_topic_score_gemma":0.0005040707,"domain_scores_codex":[0.9988167,0.000226152,0.0004403528,0.0001721214,0.0001066638,0.000237986],"domain_scores_gemma":[0.9991261,0.0004370637,0.0001728148,0.0002287693,0.0000127125,0.00002249216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.000472458,0.003492444,0.4363862,0.0001797568,0.00007704492,0.000005510743,0.01320038,0.0001229784,0.0001325846,0.06332683,4.589623e-7,0.4826033],"study_design_scores_gemma":[0.005228585,0.001293476,0.978981,0.0001926267,0.0002125293,0.00005178757,0.002108763,0.0001976648,0.000851502,0.006661616,0.004115105,0.0001053349],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9189786,0.07860059,0.0001228304,0.0004969243,0.00007263336,0.001098429,0.00000172672,0.000005844568,0.0006224578],"genre_scores_gemma":[0.9254816,0.07419055,0.0001727111,0.00005188874,0.00001978263,0.00006349016,0.000006145508,0.000008483737,0.000005396445],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5425948,"threshold_uncertainty_score":0.3497636,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3034142645","doi":"10.1177/2040620720914490","title":"PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Context (archaeology); Oncology; Hodgkin lymphoma; Interim; Regimen; Lymphoma; Internal medicine; Radiation therapy; Clinical trial; Toxicity; Stage (stratigraphy); Medical physics","authors":[{"name":"Noémie Lang","is_ca":true},{"name":"Michael Crump","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1572027979134116,"gpt":0.369600646188655,"spread":0.2123978482752434,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001713839,0.0008998202,0.004915356,0.0003347195,0.00007411087,0.00001634236,0.0003818734,0.0003150908,0.00004182863],"category_scores_gemma":[0.00005647408,0.0006552077,0.0006940283,0.0006051949,0.0001299302,0.0001080396,0.00009123239,0.0001894838,0.00008509144],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006258963,"about_ca_system_score_gemma":0.0006365341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002699492,"about_ca_topic_score_gemma":0.000007520785,"domain_scores_codex":[0.9965652,0.0002053188,0.001080732,0.001160571,0.0002628878,0.0007252903],"domain_scores_gemma":[0.9975153,0.001018114,0.0004244985,0.000737224,0.00004737141,0.0002575459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000777168,0.000804604,0.00005144351,0.00817229,0.000480196,0.000297384,0.0001001193,0.000002624627,4.801693e-7,0.006727757,0.00004033949,0.9825456],"study_design_scores_gemma":[0.005354257,0.00125562,0.00003173211,0.004392304,0.0006288972,0.001258674,0.00004004599,0.00001385466,0.0000317555,0.00107242,0.9853629,0.0005575519],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003935805,0.9899182,0.0006897453,0.0009098067,0.0003496051,0.006647882,0.00005660804,0.0001436032,0.001245172],"genre_scores_gemma":[0.000420688,0.9819908,0.008818825,0.00155249,0.0001481239,0.006516568,0.0002929387,0.0001646783,0.00009486686],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9853225,"threshold_uncertainty_score":0.9995899,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386205570","doi":"10.1177/20406207231195594","title":"Luspatercept for transfusion-dependent β-thalassemia: time to get real","year":2023,"lang":"en","type":"editorial","venue":"Therapeutic Advances in Hematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"bluebird bio; Ionis Pharmaceuticals; La Jolla Pharmaceutical Company; Alexion Pharmaceuticals; Vertex Pharmaceuticals; Celgene; Sanofi; Amgen; Vifor Pharma; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Thalassemia; Blood transfusion; Intensive care medicine; Internal medicine","authors":[{"name":"Khaled M. Musallam","is_ca":false},{"name":"Sujit Sheth","is_ca":false},{"name":"Maria Domenica Cappellini","is_ca":false},{"name":"Antonis Kattamis","is_ca":false},{"name":"Kevin H.M. Kuo","is_ca":true},{"name":"Alì Taher","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009589591266610426,"gpt":0.3126826305464226,"spread":0.3030930392798122,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004321084,0.0005351427,0.001566236,0.0004102023,0.00009297283,0.00001321069,0.0003354764,0.001929503,0.000353767],"category_scores_gemma":[0.0003251811,0.0004520022,0.0002493836,0.0003709146,0.0001418399,0.00007019655,0.00007656638,0.001089431,0.0008287823],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002283489,"about_ca_system_score_gemma":0.0003556691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006107332,"about_ca_topic_score_gemma":0.0001856819,"domain_scores_codex":[0.9967706,0.0001106698,0.0008322039,0.0008824435,0.0005177573,0.0008863713],"domain_scores_gemma":[0.997104,0.001794181,0.0001747036,0.000547214,0.0001740348,0.0002058413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004361739,0.0006230588,0.0002107424,0.002993554,0.0004887119,0.000654568,0.001852968,0.0002758612,0.0005925386,0.0003949463,0.900616,0.08693529],"study_design_scores_gemma":[0.003378629,0.000959772,0.00001167108,0.0007427512,0.0002821329,0.00006143442,0.0002807074,0.0001685361,0.0001386207,0.001840926,0.9916357,0.0004991163],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.001892161,0.01243271,0.001610683,0.002874503,0.9712424,0.004080356,0.0003091081,0.0005404325,0.005017698],"genre_scores_gemma":[0.004475975,0.2036438,0.003346541,0.001985346,0.7171723,0.005197027,0.004326804,0.001720861,0.05813133],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.25407,"threshold_uncertainty_score":0.9999492,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4295903721","doi":"10.1177/20406207221118429","title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to &lt;100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPAND","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Genentech; AOP Orphan; Sierra Oncology; CTI Biopharma; Incyte; FibroGen; Gilead Sciences; BeiGene; Sanofi; MorphoSys; Celgene; AstraZeneca; Novartis; Pfizer; Amgen","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Adverse effect; Internal medicine; Clinical endpoint; Anemia; Phases of clinical research; Gastroenterology; Discontinuation; International Prognostic Scoring System; Clinical trial; Bone marrow; Myelodysplastic syndromes","authors":[{"name":"Paola Guglielmelli","is_ca":false},{"name":"Jean‐Jacques Kiladjian","is_ca":false},{"name":"Alessandro M. Vannucchi","is_ca":false},{"name":"Minghui Duan","is_ca":false},{"name":"Haitao Meng","is_ca":false},{"name":"Ling Pan","is_ca":false},{"name":"Guangsheng He","is_ca":false},{"name":"Srđan Verstovšek","is_ca":false},{"name":"Françoise Boyer","is_ca":false},{"name":"Fiorenza Barraco","is_ca":false},{"name":"Dietger Niederwieser","is_ca":false},{"name":"Ester Pungolino","is_ca":false},{"name":"Anna Marina Liberati","is_ca":false},{"name":"Claire Harrison","is_ca":false},{"name":"Pantelia Roussou","is_ca":false},{"name":"Monika Wroclawska","is_ca":false},{"name":"Divyadeep Karumanchi","is_ca":false},{"name":"Karen Sinclair","is_ca":false},{"name":"Peter A.W. te Boekhorst","is_ca":false},{"name":"Heinz Gisslinger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01325738480847344,"gpt":0.2773913357063457,"spread":0.2641339508978723,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004539007,0.0003442777,0.001352743,0.000450106,0.0001482159,0.000006998942,0.0001525407,0.00008869635,0.001033549],"category_scores_gemma":[0.00008779063,0.0002328384,0.00008634811,0.0009057756,0.0003518783,0.0000825902,0.0001764427,0.0002147937,0.000003036932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001508836,"about_ca_system_score_gemma":0.00007780828,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000456813,"about_ca_topic_score_gemma":0.0001147284,"domain_scores_codex":[0.9973565,0.0003710128,0.0008302462,0.0005792908,0.0004474305,0.0004155199],"domain_scores_gemma":[0.9974508,0.001573325,0.0002802827,0.0004528208,0.0001289394,0.0001138535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01799018,0.00173793,0.9229407,0.0002697856,0.001098614,0.00004851326,0.005118588,0.02711391,0.00002821303,0.0008638612,0.00004565844,0.02274411],"study_design_scores_gemma":[0.04101514,0.009886449,0.8957158,0.0007160172,0.002512103,0.0002027103,0.003909707,0.0221569,0.003134487,0.0003659642,0.01945017,0.0009345902],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993197,0.004626224,0.0000557991,0.0005415898,0.00001640179,0.001224775,0.0001988012,0.00001239097,0.0001270827],"genre_scores_gemma":[0.9976799,0.0008520269,0.0004474908,0.0004257932,0.00001173931,0.00031163,0.0001551063,0.00002755356,0.00008879689],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02722489,"threshold_uncertainty_score":0.9998797,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391890091","doi":"10.1177/20406207231218624","title":"The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"Takeda Pharmaceuticals International; Grifols; Swedish Orphan Biovitrum; Baxalta; CSL Behring; Biogen; Novo Nordisk; Sanofi; Pfizer","keywords":"Medicine; Observational study; Interim analysis; Clinical endpoint; Adverse effect; Quality of life (healthcare); Internal medicine; Clinical trial; Pediatrics; Physical therapy","authors":[{"name":"Margareth C. Ozelo","is_ca":false},{"name":"Cédric Hermans","is_ca":false},{"name":"Manuel Carção","is_ca":true},{"name":"Benoît Guillet","is_ca":false},{"name":"Joan Gu","is_ca":false},{"name":"Randy Guerra","is_ca":false},{"name":"Leilei Tang","is_ca":false},{"name":"Kate Khair","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01639607912888928,"gpt":0.3499241047546473,"spread":0.333528025625758,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004809097,0.0001201637,0.0003694571,0.0001679563,0.00003689641,0.00000492971,0.0001642765,0.00003835636,0.0000138464],"category_scores_gemma":[0.00005871394,0.00005752874,0.00003723057,0.000479781,0.0002372694,0.00005591634,0.00008804024,0.0001765299,0.00000196508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007916988,"about_ca_system_score_gemma":0.00006598447,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004712847,"about_ca_topic_score_gemma":0.0007668645,"domain_scores_codex":[0.9987398,0.0002541064,0.0003026399,0.0002306227,0.0002847386,0.0001880834],"domain_scores_gemma":[0.9986772,0.0009122737,0.00004715495,0.0002535277,0.00007864594,0.00003119967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005434992,0.000258967,0.9675235,0.000162198,0.0001551461,0.00001155992,0.0009428697,0.000009900383,0.00003856342,0.005727547,0.000001691568,0.01973305],"study_design_scores_gemma":[0.00623622,0.0009436219,0.9869265,0.000612544,0.00004796958,0.000006307174,0.0005784651,0.0000425268,0.001103127,0.002649766,0.0007786885,0.00007429611],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948958,0.001370793,0.0000157939,0.0006680041,0.0003510746,0.001905103,0.000005642387,0.000008765088,0.0007789926],"genre_scores_gemma":[0.9992844,0.0002888232,0.00002475509,0.00001927944,0.00001179771,0.0001159181,0.000002356328,0.00001364045,0.0002390432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01965875,"threshold_uncertainty_score":0.2345954,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4381855175","doi":"10.1177/20406207231177282","title":"Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Sierra Oncology; National Cancer Institute; Galecto; Incyte; Servier; Celgene","keywords":"Medicine; Myelofibrosis; Essential thrombocythemia; Polycythemia vera; Bone marrow; Internal medicine; Myeloid leukemia; Myeloproliferative neoplasm; Oncology; Population; Myeloid; Acute leukemia; Haematopoiesis; Leukemia; Immunology; Stem cell","authors":[{"name":"Helen Ajufo","is_ca":false},{"name":"Julian A. Waksal","is_ca":false},{"name":"John Mascarenhas","is_ca":false},{"name":"Raajit K. Rampal","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.170944473417937,"gpt":0.4451018780176871,"spread":0.2741574045997501,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002499624,0.0008592476,0.003795922,0.0004632942,0.0001402859,0.00003961061,0.0001152931,0.0004777361,0.00003608828],"category_scores_gemma":[0.00008550989,0.0006077031,0.0001447911,0.0004367064,0.0005094393,0.0001686038,0.0001195959,0.0005463269,0.00002959979],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000113979,"about_ca_system_score_gemma":0.0002119686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003241206,"about_ca_topic_score_gemma":0.00009211721,"domain_scores_codex":[0.9967388,0.0003725153,0.0009922836,0.001069545,0.0002119949,0.0006148904],"domain_scores_gemma":[0.9975371,0.001368702,0.0004560894,0.0003548561,0.00008949718,0.0001937184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001487775,0.000455922,0.0005999783,0.02110151,0.0006296039,0.0005097332,0.0008328973,2.260515e-7,1.334716e-7,0.009505404,0.000003110926,0.9662127],"study_design_scores_gemma":[0.01049667,0.003432743,0.0001600846,0.04541438,0.002979521,0.006226661,0.001217997,0.0002501434,0.0000562539,0.00307398,0.9252795,0.00141206],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008935349,0.9952183,0.000008945384,0.0005460567,0.0001331734,0.002687521,0.00003684026,0.0001488565,0.000326789],"genre_scores_gemma":[0.0009677737,0.9957309,0.0005674763,0.00008028285,0.000101548,0.002266001,0.00009679278,0.0001251377,0.00006410274],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9648007,"threshold_uncertainty_score":0.9996374,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405416708","doi":"10.1177/20406207241298088","title":"Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Agios Pharmaceuticals; Vertex Pharmaceuticals; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Blood transfusion; Thalassemia; Internal medicine; Retrospective cohort study; Demographics; Anemia; Hemoglobin; Medical record; Pediatrics; Gastroenterology; Surgery; Demography","authors":[{"name":"Maria Domenica Cappellini","is_ca":false},{"name":"Mrudula B. Glassberg","is_ca":false},{"name":"Juliana Meyers","is_ca":false},{"name":"Maria Jimenez","is_ca":false},{"name":"Tram Nham","is_ca":false},{"name":"Luciana Bueno","is_ca":false},{"name":"Jan Sieluk","is_ca":false},{"name":"Aylin Yücel","is_ca":false},{"name":"Ferras Alashkar","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01450649536129391,"gpt":0.3364064701540063,"spread":0.3218999747927124,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003140169,0.0002749428,0.0008116022,0.0002560849,0.00006365634,0.00001787518,0.00006760413,0.0002752295,0.0001167536],"category_scores_gemma":[0.00004066167,0.0001814238,0.00008385197,0.0003201345,0.0003679646,0.0001436289,0.00002840368,0.0006677359,0.000007196525],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001325612,"about_ca_system_score_gemma":0.00009240057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002867639,"about_ca_topic_score_gemma":0.00366578,"domain_scores_codex":[0.9979156,0.0001349721,0.0007106035,0.0006014531,0.0003029542,0.0003343856],"domain_scores_gemma":[0.998988,0.0003662185,0.000146859,0.0002561591,0.00006779352,0.000174941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003981596,0.001198297,0.8907009,0.00009592428,0.0003270403,0.0004704017,0.000303306,1.99124e-7,2.148275e-7,0.0003766343,0.00000373029,0.1061252],"study_design_scores_gemma":[0.0028488,0.00258281,0.9915836,0.0004291515,0.0003324304,0.00006615308,0.000556601,0.0001537377,0.000003344837,0.0002740889,0.000992192,0.0001770988],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951241,0.002137484,0.0001141366,0.0004430648,0.0006593748,0.0009539087,0.00001067163,0.000110605,0.0004466297],"genre_scores_gemma":[0.984449,0.01509879,0.00005397861,0.00009025799,0.00007703849,0.00008230758,0.00003350313,0.00003872167,0.00007645482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1059481,"threshold_uncertainty_score":0.7398247,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4412014975","doi":"10.1177/20406207251342199","title":"Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"AOP Orphan; Swedish Orphan Biovitrum; Novartis Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Celgene; Alexion Pharmaceuticals; Ariad Pharmaceuticals; Gilead Sciences; RWTH Aachen University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Phlebotomy; Internal medicine; Polycythemia vera; Thrombosis; Hematology; Retrospective cohort study; Myelofibrosis; Gastroenterology; Surgery; Bone marrow","authors":[{"name":"Steffen Koschmieder","is_ca":false},{"name":"Clemens Schulte","is_ca":false},{"name":"Eyck von der Heyde","is_ca":false},{"name":"Lambert Busque","is_ca":true},{"name":"Françoise Boyer‐Perrard","is_ca":false},{"name":"Timothy Devos","is_ca":false},{"name":"Francesco Passamonti","is_ca":false},{"name":"Wendy Y. Cheng","is_ca":false},{"name":"Mu Cheng","is_ca":false},{"name":"Marja Nuortti","is_ca":false},{"name":"Volker Baum","is_ca":false},{"name":"Claire Harrison","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02571890817822953,"gpt":0.3605291126465878,"spread":0.3348102044683583,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008043071,0.0004792247,0.001514411,0.0002023977,0.0001087354,0.00001354208,0.0003325139,0.0001803914,0.00006189715],"category_scores_gemma":[0.0008534862,0.0002757427,0.0001559177,0.0005930889,0.0001956268,0.00009178223,0.0001315226,0.0004242828,0.00002516029],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001376793,"about_ca_system_score_gemma":0.000199718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004171328,"about_ca_topic_score_gemma":0.001656243,"domain_scores_codex":[0.9962878,0.0006604139,0.001247194,0.0008747062,0.0004217621,0.0005081185],"domain_scores_gemma":[0.9895106,0.008629901,0.0003208127,0.001124873,0.0002471432,0.0001666998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2087024,0.002595971,0.7724775,0.000009043789,0.0008599288,0.00004401672,0.002754008,0.00009693016,0.000003171329,0.0001168781,0.00002054284,0.01231956],"study_design_scores_gemma":[0.04030571,0.008209321,0.9470092,0.0002217209,0.000322399,0.000001752699,0.0009367248,0.00001716472,0.0006294166,0.0003178457,0.001784288,0.0002444728],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871146,0.00125775,0.0004208772,0.007382772,0.0004282783,0.00313346,0.0001546907,0.00004199068,0.00006555186],"genre_scores_gemma":[0.994081,0.0004923532,0.002047064,0.00243129,0.00005145006,0.0007591841,0.00002685888,0.00004124988,0.0000696163],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1745317,"threshold_uncertainty_score":0.9999695,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4415458924","doi":"10.1177/20406207251388051","title":"Immunoglobulin treatment and clinical outcomes: data from the Ontario Immunoglobulin Treatment program multicenter case registry","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"McMaster University; University of Ottawa; Sault Area Hospital; Public Health Ontario; University of Toronto; Ottawa Hospital","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Antibody; Clinical trial; Antibody therapy; Health care; Multicenter study; Healthcare system; MEDLINE","authors":[{"name":"Sarah Shehadeh","is_ca":true},{"name":"Stephen Betschel","is_ca":true},{"name":"D. William Cameron","is_ca":true},{"name":"Danny Hill","is_ca":true},{"name":"Susan Waserman","is_ca":true},{"name":"Juthaporn Cowan","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06523791734071023,"gpt":0.4231188872636341,"spread":0.3578809699229239,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001505401,0.0004049171,0.00109797,0.000054807,0.0001432643,0.00002893311,0.0002723561,0.0002082247,0.00009277908],"category_scores_gemma":[0.00005049552,0.000228512,0.0001488734,0.0001308575,0.000387441,0.0001290411,0.0001559921,0.0002468693,0.00002712086],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004054231,"about_ca_system_score_gemma":0.000239565,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0213987,"about_ca_topic_score_gemma":0.1171047,"domain_scores_codex":[0.9977983,0.0001899989,0.0007553821,0.0007441547,0.00009358579,0.0004186276],"domain_scores_gemma":[0.9970792,0.001072085,0.0001762148,0.001567545,0.00002932234,0.00007566328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001101174,0.003083539,0.7390096,0.00001508592,0.001419599,0.004055667,0.000454567,0.000001276493,0.000001288745,0.0001281804,0.00001619053,0.2507139],"study_design_scores_gemma":[0.05959834,0.004553418,0.4936804,0.0005464794,0.004121087,0.007532062,0.003397467,0.001036577,0.0001168024,0.004044424,0.4205983,0.0007747205],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9387807,0.05600545,0.00008201267,0.002026405,0.0004011959,0.001870511,0.00008966576,0.00007354188,0.0006704922],"genre_scores_gemma":[0.9827448,0.01207994,0.002695818,0.0008395503,0.00002559596,0.000257552,0.0003578012,0.00002252806,0.0009763911],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4205821,"threshold_uncertainty_score":0.9851179,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7116052349","doi":"10.1177/20406207251401313","title":"The efficacy and safety of anti-CD20 antibody for the treatment of B-ALL: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Meta-analysis; Clinical trial; Adverse effect; Antibody; Systematic review; Randomized controlled trial; MEDLINE","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.04353487925067105,"gpt":0.4129634762267176,"spread":0.3694285969760466,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006292706,0.0001619826,0.002422756,0.0001220457,0.00006771946,0.000004215923,0.0001516604,0.0000548147,0.000009977991],"category_scores_gemma":[0.0002558709,0.00006722506,0.0002783148,0.0004866478,0.0005099048,0.0000269136,0.00003534321,0.00005784844,2.865528e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005654473,"about_ca_system_score_gemma":0.00008800146,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001511476,"about_ca_topic_score_gemma":0.00002754509,"domain_scores_codex":[0.9984499,0.0002376643,0.0007389461,0.0002231218,0.0001420353,0.0002082877],"domain_scores_gemma":[0.9915372,0.007528941,0.0002568393,0.0005443607,0.0001055125,0.0000271878],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.002854759,0.001370321,0.00444816,0.4232439,0.4705679,0.00002992665,0.001747897,0.0001382637,0.0004074298,0.08843723,0.00002700398,0.006727149],"study_design_scores_gemma":[0.006864173,0.001110926,0.0009500091,0.002496424,0.976069,0.0001851426,0.0006518707,0.004324112,0.001163266,0.002799115,0.003201179,0.0001847965],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.002918965,0.9788414,0.009284782,0.004928574,0.00002209027,0.003910001,0.00001472734,0.000007914125,0.00007152535],"genre_scores_gemma":[0.6739624,0.3244609,0.000416324,0.0005338181,0.000003411068,0.0004186549,0.000005317186,0.00001052279,0.0001886283],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.6710435,"threshold_uncertainty_score":0.2741358,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}